Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

  • Quoted phrase not found.
1.

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder.

Palis H, Marchand K, Karamouzian M, MacDonald S, Harrison S, Guh D, Lock K, Brissette S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Addict Behav Rep. 2018 Mar 27;7:82-89. doi: 10.1016/j.abrep.2018.03.005. eCollection 2018 Jun.

2.

Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.

Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, Krausz M, MacDonald S, Marsh DC, Schechter MT, Anis AH.

Addiction. 2018 Jul;113(7):1264-1273. doi: 10.1111/add.14171. Epub 2018 Mar 28.

PMID:
29589873
3.

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.

Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, Anis A.

Cost Eff Resour Alloc. 2017 Sep 7;15:20. doi: 10.1186/s12962-017-0081-8. eCollection 2017.

4.

Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis.

Bansback N, Fu E, Sun H, Guh D, Zhang W, Lacaille D, Milbers K, Anis AH.

Curr Rheumatol Rep. 2017 Sep;19(9):54. doi: 10.1007/s11926-017-0680-6. Review.

PMID:
28752490
5.

Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort.

Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, Anis AH.

J Rheumatol. 2017 Oct;44(10):1436-1444. doi: 10.3899/jrheum.161399. Epub 2017 Jul 1.

PMID:
28668809
6.

Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.

Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Rev. 2018 Jan;37(1):137-146. doi: 10.1111/dar.12573. Epub 2017 Jun 8.

PMID:
28593748
7.

Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.

Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Subst Abuse Treat Prev Policy. 2017 May 19;12(1):25. doi: 10.1186/s13011-017-0110-9.

8.

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Depend. 2017 Jul 1;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. Epub 2017 May 10.

PMID:
28521199
9.

The impact of price-cap regulations on market entry by generic pharmaceutical firms.

Zhang W, Sun H, Guh D, Anis AH.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):231-238. doi: 10.1080/14737167.2017.1271717. Epub 2016 Dec 27.

PMID:
27936981
10.

The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.

Zhang W, Guh D, Sun H, Marra CA, Lynd LD, Anis AH.

Med Care. 2016 Sep;54(9):884-90. doi: 10.1097/MLR.0000000000000577.

PMID:
27213540
11.

Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort.

Harvard S, Guh D, Bansback N, Richette P, Dougados M, Anis A, Fautrel B.

RMD Open. 2016 Apr 4;2(1):e000230. doi: 10.1136/rmdopen-2015-000230. eCollection 2016.

12.

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT.

JAMA Psychiatry. 2016 May 1;73(5):447-55. doi: 10.1001/jamapsychiatry.2016.0109.

PMID:
27049826
13.

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency.

Oviedo-Joekes E, Marchand K, Lock K, MacDonald S, Guh D, Schechter MT.

Subst Abuse Treat Prev Policy. 2015 Jan 26;10:3. doi: 10.1186/1747-597X-10-3.

14.

Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.

Oviedo-Joekes E, Sordo L, Guh D, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Addict Behav. 2015 Feb;41:81-6. doi: 10.1016/j.addbeh.2014.10.003. Epub 2014 Oct 7.

15.

Long-term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonseptic critical illness and of the general population.

Linder A, Guh D, Boyd JH, Walley KR, Anis AH, Russell JA.

Crit Care Med. 2014 Oct;42(10):2211-8. doi: 10.1097/CCM.0000000000000503.

PMID:
25054672
16.

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.

Oviedo-Joekes E, Guh D, Marchand K, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT.

Subst Abuse Treat Prev Policy. 2014 Jun 8;9:23. doi: 10.1186/1747-597X-9-23.

17.

The effect of direct-to-consumer genetic tests on anticipated affect and health-seeking behaviors: a pilot survey.

Bansback N, Sizto S, Guh D, Anis AH.

Genet Test Mol Biomarkers. 2012 Oct;16(10):1165-71. doi: 10.1089/gtmb.2012.0074. Epub 2012 Aug 29.

PMID:
22931244
18.

Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH.

CMAJ. 2012 Apr 3;184(6):E317-28. doi: 10.1503/cmaj.110669. Epub 2012 Mar 12.

19.

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment.

Marchand K, Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Schechter MT.

Harm Reduct J. 2012 Jan 25;9:8. doi: 10.1186/1477-7517-9-8.

20.

Work disability rates in RA. Results from an inception cohort with 24 years follow-up.

Nikiphorou E, Guh D, Bansback N, Zhang W, Dixey J, Williams P, Young A.

Rheumatology (Oxford). 2012 Feb;51(2):385-92. doi: 10.1093/rheumatology/ker401. Epub 2012 Jan 11.

PMID:
22237045

Supplemental Content

Loading ...
Support Center